Ocular Hypertension Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major ocular hypertension markets reached a value of US$ 3,054.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4,538.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.67% during 2024-2034.
The ocular hypertension market has been comprehensively analyzed in IMARC's new report titled "Ocular Hypertension Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ocular hypertension refers to a condition characterized by higher-than-normal intraocular pressure (IOP) in the eye. Intraocular pressure is the fluid pressure inside the eye, maintained by the balance between the production and drainage of fluid called aqueous humor. Most people suffering from ocular hypertension are asymptomatic, but some patients may occasionally experience mild eye discomfort, including a feeling of pressure or aching in the eye. In rare cases, ocular hypertension may be accompanied by mild headaches, particularly around the temples or in the forehead. The diagnosis of ocular hypertension is typically made during a comprehensive eye examination. The main diagnostic criterion is the measurement of intraocular pressure using instruments like a tonometer. In general, an IOP reading of 21 mmHg or higher is considered elevated and indicative of ocular hypertension. The eye care professional may also assess the optic nerve through various techniques, such as ophthalmoscopy and optical coherence tomography (OCT). Additionally, a thorough examination of the anterior chamber angle may be performed to assess the drainage structures of the eye.
The escalating cases of inflammation, scarring, or structural abnormalities in the eye resulting from trauma or surgery, which can impair the proper outflow of aqueous humor, are primarily driving the ocular hypertension market. In addition to this, the rising prevalence of several associated risk factors, including genetic predisposition, age-related changes in the eye's drainage system, underlying systemic conditions like diabetes, prolonged use of corticosteroids, etc., is also bolstering the market growth. Furthermore, the inflating adoption of topical eye drops to lower elevated intraocular pressure by increasing the outflow of aqueous humor or reducing its production is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cyclophotocoagulation, which uses laser or cryotherapy to target the ciliary body, thereby lowering its ability to produce aqueous humor, is also creating a positive outlook for the market. Apart from this, the escalating utilization of selective laser trabeculoplasty on account of its several associated benefits, such as targeted treatment without damaging surrounding tissues, minimal downtime and quick recovery, potential long-term advantages with sustained intraocular pressure control, etc., is expected to drive the ocular hypertension market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the ocular hypertension market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for ocular hypertension and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ocular hypertension market in any manner.
Recent Developments:
In February 2024, Skye Bioscience, Inc. declared that it had dosed 56 patients with SBI-100 Ophthalmic Emulsion (OE) in its Phase 2a trial and completed final study visits for all patients. SBI-100 OE refers to a cannabinoid receptor type 1 agonist that is applied topically to the eye. It is being developed to meet the unmet requirements of patients with increased intraocular pressure caused by ocular hypertension.
In February 2024, Nicox SA announced the signing of an agreement that grants Kowa Company, Ltd. exclusive Japanese rights to develop and commercialize NCX 470, Nicox'sNicox's nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of IOP in patients with ocular hypertension.
In December 2023, Glaukos reported that the FDA had approved a New Drug Application (NDA) for its iDose TR (travoprost intracameral) implant. This approval permits for iDose TR 75 mcg to be administered once per eye. The indication for the prostaglandin analog includes the decrease of IOP in individuals with ocular hypertension.
In September 2023, MERCURY-3 trial findings, which were published in the Graefe'sGraefe's Archive for Clinical and Experimental Ophthalmology, support the addition of Roclanda (latanoprost/netarsudil) as an alternative fixed-dose combination (FDC) treatment option for people affected with ocular hypertension.
Key Highlights:
The population prevalence estimates for ocular hypertension range from 4.5% to 9.4% for people older than 40 years, with frequency increasing with age.
African Caribbeans are more at risk for ocular hypertension, having the highest prevalence of the disease worldwide (12.6%).
In the United States, the incidence of ocular hypertension among non-Hispanic Whites aged 40 and above is 4.5 percent, rising to 7.7 percent in those aged 75 to 79.
According to research findings, around 10% of persons with untreated ocular hypertension develop primary open-angle glaucoma in five years.
Women have a higher risk of developing ocular hypertension than men.
Drugs:
Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a mixture of two prescription drugs that relieve high eye pressure (IOP) in people with open-angle glaucoma or ocular hypertension. The drug is recommended to be administered at a dosage of one drop once daily in the evening in the affected eye(s).
AGN-193408 sustained release is under clinical development by AbbVie for the treatment of ocular hypertension. This therapeutic candidate works by targeting the prostaglandin F2 alpha receptor and is administered as an implant via the ocular method.
QLS-101 is a new ATP-sensitive potassium (KATP) channel modulator delivered as a topical eyedrop. It addresses distal outflow resistance and episcleral venous pressure (EVP), which are important components of IOP. It also reduces IOP by expanding outflow channels and episcleral arteries in the eye distal to the trabecular meshwork.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ocular hypertension market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ocular hypertension market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current ocular hypertension marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the ocular hypertension market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the ocular hypertension market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the ocular hypertension market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of ocular hypertension across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of ocular hypertension by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of ocular hypertension by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with ocular hypertension across the seven major markets?
What is the size of the ocular hypertension patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of ocular hypertension?
What will be the growth rate of patients across the seven major markets?
Ocular Hypertension: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for ocular hypertension drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ocular hypertension market?
What are the key regulatory events related to the ocular hypertension market?
What is the structure of clinical trial landscape by status related to the ocular hypertension market?
What is the structure of clinical trial landscape by phase related to the ocular hypertension market?
What is the structure of clinical trial landscape by route of administration related to the ocular hypertension market?
The ocular hypertension market has been comprehensively analyzed in IMARC's new report titled "Ocular Hypertension Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ocular hypertension refers to a condition characterized by higher-than-normal intraocular pressure (IOP) in the eye. Intraocular pressure is the fluid pressure inside the eye, maintained by the balance between the production and drainage of fluid called aqueous humor. Most people suffering from ocular hypertension are asymptomatic, but some patients may occasionally experience mild eye discomfort, including a feeling of pressure or aching in the eye. In rare cases, ocular hypertension may be accompanied by mild headaches, particularly around the temples or in the forehead. The diagnosis of ocular hypertension is typically made during a comprehensive eye examination. The main diagnostic criterion is the measurement of intraocular pressure using instruments like a tonometer. In general, an IOP reading of 21 mmHg or higher is considered elevated and indicative of ocular hypertension. The eye care professional may also assess the optic nerve through various techniques, such as ophthalmoscopy and optical coherence tomography (OCT). Additionally, a thorough examination of the anterior chamber angle may be performed to assess the drainage structures of the eye.
The escalating cases of inflammation, scarring, or structural abnormalities in the eye resulting from trauma or surgery, which can impair the proper outflow of aqueous humor, are primarily driving the ocular hypertension market. In addition to this, the rising prevalence of several associated risk factors, including genetic predisposition, age-related changes in the eye's drainage system, underlying systemic conditions like diabetes, prolonged use of corticosteroids, etc., is also bolstering the market growth. Furthermore, the inflating adoption of topical eye drops to lower elevated intraocular pressure by increasing the outflow of aqueous humor or reducing its production is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cyclophotocoagulation, which uses laser or cryotherapy to target the ciliary body, thereby lowering its ability to produce aqueous humor, is also creating a positive outlook for the market. Apart from this, the escalating utilization of selective laser trabeculoplasty on account of its several associated benefits, such as targeted treatment without damaging surrounding tissues, minimal downtime and quick recovery, potential long-term advantages with sustained intraocular pressure control, etc., is expected to drive the ocular hypertension market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the ocular hypertension market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for ocular hypertension and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ocular hypertension market in any manner.
Recent Developments:
In February 2024, Skye Bioscience, Inc. declared that it had dosed 56 patients with SBI-100 Ophthalmic Emulsion (OE) in its Phase 2a trial and completed final study visits for all patients. SBI-100 OE refers to a cannabinoid receptor type 1 agonist that is applied topically to the eye. It is being developed to meet the unmet requirements of patients with increased intraocular pressure caused by ocular hypertension.
In February 2024, Nicox SA announced the signing of an agreement that grants Kowa Company, Ltd. exclusive Japanese rights to develop and commercialize NCX 470, Nicox'sNicox's nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of IOP in patients with ocular hypertension.
In December 2023, Glaukos reported that the FDA had approved a New Drug Application (NDA) for its iDose TR (travoprost intracameral) implant. This approval permits for iDose TR 75 mcg to be administered once per eye. The indication for the prostaglandin analog includes the decrease of IOP in individuals with ocular hypertension.
In September 2023, MERCURY-3 trial findings, which were published in the Graefe'sGraefe's Archive for Clinical and Experimental Ophthalmology, support the addition of Roclanda (latanoprost/netarsudil) as an alternative fixed-dose combination (FDC) treatment option for people affected with ocular hypertension.
Key Highlights:
The population prevalence estimates for ocular hypertension range from 4.5% to 9.4% for people older than 40 years, with frequency increasing with age.
African Caribbeans are more at risk for ocular hypertension, having the highest prevalence of the disease worldwide (12.6%).
In the United States, the incidence of ocular hypertension among non-Hispanic Whites aged 40 and above is 4.5 percent, rising to 7.7 percent in those aged 75 to 79.
According to research findings, around 10% of persons with untreated ocular hypertension develop primary open-angle glaucoma in five years.
Women have a higher risk of developing ocular hypertension than men.
Drugs:
Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a mixture of two prescription drugs that relieve high eye pressure (IOP) in people with open-angle glaucoma or ocular hypertension. The drug is recommended to be administered at a dosage of one drop once daily in the evening in the affected eye(s).
AGN-193408 sustained release is under clinical development by AbbVie for the treatment of ocular hypertension. This therapeutic candidate works by targeting the prostaglandin F2 alpha receptor and is administered as an implant via the ocular method.
QLS-101 is a new ATP-sensitive potassium (KATP) channel modulator delivered as a topical eyedrop. It addresses distal outflow resistance and episcleral venous pressure (EVP), which are important components of IOP. It also reduces IOP by expanding outflow channels and episcleral arteries in the eye distal to the trabecular meshwork.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ocular hypertension market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ocular hypertension market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current ocular hypertension marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the ocular hypertension market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the ocular hypertension market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the ocular hypertension market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of ocular hypertension across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of ocular hypertension by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of ocular hypertension by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with ocular hypertension across the seven major markets?
What is the size of the ocular hypertension patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of ocular hypertension?
What will be the growth rate of patients across the seven major markets?
Ocular Hypertension: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for ocular hypertension drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ocular hypertension market?
What are the key regulatory events related to the ocular hypertension market?
What is the structure of clinical trial landscape by status related to the ocular hypertension market?
What is the structure of clinical trial landscape by phase related to the ocular hypertension market?
What is the structure of clinical trial landscape by route of administration related to the ocular hypertension market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OCULAR HYPERTENSION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OCULAR HYPERTENSION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OCULAR HYPERTENSION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OCULAR HYPERTENSION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OCULAR HYPERTENSION - UNMET NEEDS
10 OCULAR HYPERTENSION - KEY ENDPOINTS OF TREATMENT
11 OCULAR HYPERTENSION - MARKETED PRODUCTS
11.1 List of Ocular Hypertension Marketed Drugs Across the Top 7 Markets
11.1.1 Rocklatan (Latanoprost/netarsudil) - Alcon
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Durysta (Bimatoprost sustained-release) - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Lumigan (Bimatoprost) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Vyzulta (Latanoprostene bunod) - Bausch & Lomb
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Rescula (Unoprostone) - R-Tech Ueno Ltd
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OCULAR HYPERTENSION - PIPELINE DRUGS
12.1 List of Ocular Hypertension Pipeline Drugs Across the Top 7 Markets
12.1.1 AGN 193408 sustained-release - AbbVie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 QLS-101 - Qlaris Bio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STN 1012600 - Santen Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 NCX 470 - Nicox Ophthalmics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 OTX TIC - Ocular Therapeutix
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OCULAR HYPERTENSION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OCULAR HYPERTENSION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OCULAR HYPERTENSION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ocular Hypertension - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ocular Hypertension - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ocular Hypertension - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ocular Hypertension - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ocular Hypertension - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ocular Hypertension - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ocular Hypertension - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ocular Hypertension - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ocular Hypertension - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ocular Hypertension - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ocular Hypertension - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ocular Hypertension - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ocular Hypertension - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ocular Hypertension - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ocular Hypertension - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ocular Hypertension - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ocular Hypertension - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ocular Hypertension - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ocular Hypertension - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ocular Hypertension - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ocular Hypertension - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ocular Hypertension - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ocular Hypertension - Access and Reimbursement Overview
16 OCULAR HYPERTENSION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OCULAR HYPERTENSION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OCULAR HYPERTENSION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OCULAR HYPERTENSION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OCULAR HYPERTENSION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OCULAR HYPERTENSION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OCULAR HYPERTENSION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OCULAR HYPERTENSION - UNMET NEEDS
10 OCULAR HYPERTENSION - KEY ENDPOINTS OF TREATMENT
11 OCULAR HYPERTENSION - MARKETED PRODUCTS
11.1 List of Ocular Hypertension Marketed Drugs Across the Top 7 Markets
11.1.1 Rocklatan (Latanoprost/netarsudil) - Alcon
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Durysta (Bimatoprost sustained-release) - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Lumigan (Bimatoprost) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Vyzulta (Latanoprostene bunod) - Bausch & Lomb
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Rescula (Unoprostone) - R-Tech Ueno Ltd
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OCULAR HYPERTENSION - PIPELINE DRUGS
12.1 List of Ocular Hypertension Pipeline Drugs Across the Top 7 Markets
12.1.1 AGN 193408 sustained-release - AbbVie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 QLS-101 - Qlaris Bio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STN 1012600 - Santen Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 NCX 470 - Nicox Ophthalmics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 OTX TIC - Ocular Therapeutix
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OCULAR HYPERTENSION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OCULAR HYPERTENSION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OCULAR HYPERTENSION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ocular Hypertension - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ocular Hypertension - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ocular Hypertension - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ocular Hypertension - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ocular Hypertension - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ocular Hypertension - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ocular Hypertension - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ocular Hypertension - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ocular Hypertension - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ocular Hypertension - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ocular Hypertension - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ocular Hypertension - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ocular Hypertension - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ocular Hypertension - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ocular Hypertension - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ocular Hypertension - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ocular Hypertension - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ocular Hypertension - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ocular Hypertension - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ocular Hypertension - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ocular Hypertension - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ocular Hypertension - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ocular Hypertension - Access and Reimbursement Overview
16 OCULAR HYPERTENSION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OCULAR HYPERTENSION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OCULAR HYPERTENSION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
